Tango Therapeutics, Inc. (TNGX) Operating margin 2020–2025
Tango Therapeutics, Inc. (TNGX) operating margin by fiscal year — reported operating income divided by reported revenue.
-178.4%FY2025 · since FY2020: -681.8% → -178.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -178.4% | +167.7 pp |
| FY2024 | -346.1% | -33.5 pp |
| FY2023 | -312.6% | +134.2 pp |
| FY2022 | -446.8% | -289.7 pp |
| FY2021 | -157.1% | +524.7 pp |
| FY2020 | -681.8% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More TNGX financial trends
TNGX RevenueTNGX Net incomeTNGX Net marginTNGX Gross profitTNGX Gross marginTNGX Operating incomeTNGX Operating cash flowTNGX Free cash flowTNGX Capital expendituresTNGX Return on equityTNGX Stock buybacksTNGX Dividends paidTNGX Total assetsTNGX Total liabilitiesTNGX Shareholders’ equityTNGX overview →